MD+DI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Draft Guidance Calls for More DES Testing

An FDA draft guidance posted yesterday calls for new and longer tests to determine the safety of drug-eluting stents.

These could make it longer for them to achieve FDA approval and cost their sponsors much more money. The recommendations include longer studies in humans, larger safety databases, and more postmarket studies, reports Bloomberg News. Also included in the document is guidance on assessing the toxicity of the drug used to coat the stent, both on its own and as part of the complete product. And it has draft recommendations for engineering tests, biocompatibility tests, and animal studies to assess the device's overall safety. The guidance was put together by both CDRH and CDER. A public workshop to gather comments about the draft guidance will be announced shortly.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.